Hints and tips:
Related Special Reports
...Shares in Daiichi Sankyo jumped as much as 18 per cent after it agreed on a deal worth up to $22bn with Merck to develop and commercialise three of the Japanese pharmaceutical company’s drug candidates to...
...Daiichi Sankyo, which developed the drug with AstraZeneca and leads on marketing of the product in the UK, said it was “extremely disappointed by the decision”....
...NHS England, NICE, Daiichi Sankyo and AstraZeneca have failed people living with the disease.” Scotland approved the drug in December....
...Merck cut its full year earnings outlook because of a charge related to its $22bn partnership deal with Japanese group Daiichi Sankyo, as the US pharma group invests in cancer drugs....
...Sankyo....
...Dato-DXd, which has been developed with Japanese pharmaceutical company Daiichi Sankyo, and Enhertu, another AstraZeneca treatment, are considered by analysts to be potentially high-earning drugs....
...In 2020, AstraZeneca partnered with Daiichi Sankyo on Dato-DXd in a deal worth up to $6bn, following its agreement on Enhertu, also worth up to $6.9bn, the year before....
...Indian telco Bharti Airtel and Japan’s Daiichi Sankyo, Denso, Japan Tobacco, Mitsubishi Electric and Mitsui & Co announce second-quarter earnings....
...Ken Takeshita, global head of oncology R&D at Daiichi Sankyo, said it plans to share the data with regulators to discuss next steps....
...The drug has transformed Daiichi Sankyo into an oncology company....
...The Anglo-Swedish drugmaker published the results of its phase 3 trial for datopotamab deruxtecan, which it is developing with Daiichi Sankyo. Read more on the trial results. 5....
...Oncologists are hopeful a drug developed by AstraZeneca and Daiichi Sankyo will change how doctors treat the most common type of late-stage breast cancer, after data showed it doubled the progression-free...
...Dunoyer was AstraZeneca’s chief financial officer when it took the unusual move of raising more funds — $3.5bn — on the public market to contribute towards a $5.5bn partnership with Daiichi Sankyo....
...Japan’s Daiichi Sankyo plans to begin phase 3 clinical trials for its coronavirus vaccine this autumn with the aim of bringing the country’s first homegrown Covid-19 jab to the public in 2022....
...Japanese groups Shionogi and Daiichi Sankyo, which are developing Covid vaccines, are shifting research towards the new variant. For now, Chinese companies have an edge over regional competitors....
...The oil fund said on Wednesday that in the second quarter technology groups Alphabet, Microsoft, and Facebook made the largest positive contributions to its return while drugmaker Daiichi Sankyo, utility...
...“This will allow us to significantly increase Daiichi Sankyo’s capability,” Mr Manabe said. “We can allocate the development money that is saved to drugs other than DS-1062.”...
...Enhertu, backed by UK’s AstraZeneca and Japan’s Daiichi Sankyo, has also received FDA approval. It will be years before Gilead might recoup its cost. At worst, the deal could go the way of Kite....
...It would follow in the footsteps of a recent deal between AstraZeneca and the Japanese pharmaceutical Daiichi Sankyo to develop and market an antibody drug conjugate called DS-1062 for lung and breast cancer...
...Other Nikkei stocks that have performed strongly in recent weeks include Japan’s biggest pharmaceutical names such as Eisai and Daiichi Sankyo, factory automation leader Fanuc, and the youngest company in...
...Critically, said Blackstone, the sale lays down a price marker as Daiichi Sankyo, Eisai and others also consider sales of their OTC businesses....
...This is just the latest deal in a post-bubble spree spanning food, pharma and finance: think Daiichi-Sankyo and Ranbaxy, Kirin and Schincariol and Toshiba and Westinghouse....
...Briefly Pharma groups AstraZeneca and Daiichi Sankyo have signed a deal worth up to $6bn to develop and commercialise one of the Japanese company’s cancer drugs — the second big collaboration between the...
...A $3.5bn share issue in 2019 to pay upfront fees to Daiichi Sankyo of Japan, its partner for the breast cancer drug Enhertu, caused more disquiet....
International Edition